A detailed history of Insight Advisors, LLC transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Insight Advisors, LLC holds 4,191 shares of BMY stock, worth $244,041. This represents 0.06% of its overall portfolio holdings.

Number of Shares
4,191
Holding current value
$244,041
% of portfolio
0.06%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 15, 2024

BUY
$39.66 - $51.75 $166,215 - $216,884
4,191 New
4,191 $216,000
Q1 2024

May 06, 2024

SELL
$47.98 - $54.4 $2,303 - $2,611
-48 Reduced 1.11%
4,271 $231,000
Q4 2023

Jan 23, 2024

SELL
$48.48 - $57.85 $12,459 - $14,867
-257 Reduced 5.62%
4,319 $221,000
Q3 2023

Nov 07, 2023

SELL
$57.89 - $64.73 $100,207 - $112,047
-1,731 Reduced 27.45%
4,576 $265,000
Q2 2023

Aug 07, 2023

BUY
$63.71 - $70.74 $2,420 - $2,688
38 Added 0.61%
6,307 $403,000
Q1 2023

May 03, 2023

SELL
$65.71 - $74.53 $12,747 - $14,458
-194 Reduced 3.0%
6,269 $434,000
Q4 2022

Feb 21, 2023

BUY
$68.48 - $81.09 $8,080 - $9,568
118 Added 1.86%
6,463 $464,000
Q3 2022

Dec 12, 2022

BUY
$0.13 - $76.84 $8 - $4,994
65 Added 1.04%
6,345 $451,000
Q2 2022

Aug 11, 2022

SELL
$72.62 - $79.98 $17,501 - $19,275
-241 Reduced 3.7%
6,280 $453,000
Q1 2022

May 13, 2022

SELL
$61.48 - $73.72 $6,025 - $7,224
-98 Reduced 1.48%
6,521 $476,000
Q4 2021

Feb 09, 2022

SELL
$53.63 - $62.52 $38,613 - $45,014
-720 Reduced 9.81%
6,619 $413,000
Q3 2021

Nov 12, 2021

BUY
$59.17 - $69.31 $3,017 - $3,534
51 Added 0.7%
7,339 $435,000
Q2 2021

Aug 12, 2021

SELL
$61.91 - $67.42 $57,142 - $62,228
-923 Reduced 11.24%
7,288 $496,000
Q1 2021

May 17, 2021

BUY
$59.34 - $66.74 $24,685 - $27,763
416 Added 5.34%
8,211 $513,000
Q4 2020

Feb 12, 2021

BUY
$57.74 - $65.43 $450,083 - $510,026
7,795 New
7,795 $484,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $124B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Insight Advisors, LLC Portfolio

Follow Insight Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Insight Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Insight Advisors, LLC with notifications on news.